• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Kidney360 . Short- and Long-Term Recovery after Moderate/Severe AKI in Patients with and without COVID-19

tetano

Editor, Senior Moderator
Kidney360


. 2021 Nov 29;3(2):242-257.
doi: 10.34067/KID.0005342021. eCollection 2022 Feb 24.
Short- and Long-Term Recovery after Moderate/Severe AKI in Patients with and without COVID-19


Siao Sun[SUP] 1 [/SUP], Raji R Annadi[SUP] 2 [/SUP], Imran Chaudhri[SUP] 3 [/SUP], Kiran Munir[SUP] 3 [/SUP], Janos Hajagos[SUP] 4 [/SUP], Joel Saltz[SUP] 4 [/SUP], Minh Hoai[SUP] 2 [/SUP], Sandeep K Mallipattu[SUP] 5 [/SUP], Richard Moffitt[SUP] 4 [/SUP], Farrukh M Koraishy[SUP] 5 [/SUP]



Affiliations

Abstract

Background: Severe AKI is strongly associated with poor outcomes in coronavirus disease 2019 (COVID-19), but data on renal recovery are lacking.
Methods: We retrospectively analyzed these associations in 3299 hospitalized patients (1338 with COVID-19 and 1961 with acute respiratory illness but who tested negative for COVID-19). Uni- and multivariable analyses were used to study mortality and recovery after Kidney Disease Improving Global Outcomes Stages 2 and 3 AKI (AKI-2/3), and Machine Learning was used to predict AKI and recovery using admission data. Long-term renal function and other outcomes were studied in a subgroup of AKI-2/3 survivors.
Results: Among the 172 COVID-19-negative patients with AKI-2/3, 74% had partial and 44% complete renal recovery, whereas 12% died. Among 255 COVID-19 positive patients with AKI-2/3, lower recovery and higher mortality were noted (51% partial renal recovery, 25% complete renal recovery, 24% died). On multivariable analysis, intensive care unit admission and acute respiratory distress syndrome were associated with nonrecovery, and recovery was significantly associated with survival in COVID-19-positive patients. With Machine Learning, we were able to predict recovery from COVID-19-associated AKI-2/3 with an average precision of 0.62, and the strongest predictors of recovery were initial arterial partial pressure of oxygen and carbon dioxide, serum creatinine, potassium, lymphocyte count, and creatine phosphokinase. At 12-month follow-up, among 52 survivors with AKI-2/3, 26% COVID-19-positive and 24% COVID-19-negative patients had incident or progressive CKD.
Conclusions: Recovery from COVID-19-associated moderate/severe AKI can be predicted using admission data and is associated with severity of respiratory disease and in-hospital death. The risk of CKD might be similar between COVID-19-positive and -negative patients.

Keywords: AKI; AKI and ICU nephrology; CKD; COVID-19; Machine Learning; mortality; recovery.
 
Back
Top Bottom